Dynamics of clinical manifestations, functional state and structural changes of the pancreas, quality of life of patients with chronic pancreatitis in combination with chronic obstructive pulmonary disease under the influence of eradication of the syndrome of excessive bacterial growth in the small intestine

N. E. Monogarova, T. V. Zakomoldina, G. M. Lukashevich, O. A. Golubova, P. G. Fomenko, K. N. Borodiy, M. A. Kryuk, K. A. Voronin, L. A. Yaroshenko
{"title":"Dynamics of clinical manifestations, functional state and structural changes of the pancreas, quality of life of patients with chronic pancreatitis in combination with chronic obstructive pulmonary disease under the influence of eradication of the syndrome of excessive bacterial growth in the small intestine","authors":"N. E. Monogarova, T. V. Zakomoldina, G. M. Lukashevich, O. A. Golubova, P. G. Fomenko, K. N. Borodiy, M. A. Kryuk, K. A. Voronin, L. A. Yaroshenko","doi":"10.31146/1682-8658-ecg-204-8-17-27","DOIUrl":null,"url":null,"abstract":"The lack of efficiency in the diagnosis and treatment of chronic pancreatitis (CP) is associated with a number of objective and subjective reasons, one of which is insufficient knowledge about the pathogenesis of the disease, especially when it is combined with other internal diseases, in particular, with chronic obstructive pulmonary disease (COPD). The frequent combination of COPD and CP is associated not only with the frequency of these diseases, but also with the common links of pathogenesis, and a significant place in the pathogenesis of both diseases is occupied by the syndrome of excessive bacterial growth in the small intestine (SIBO). Aim: to increase the effectiveness of the treatment of CP in combination with COPD based on the inclusion of rifaximin and probiotic Subalin in the complex therapy of concomitant diseases. Materials and methods. We examined 128 patients with CP in the stage of exacerbation in combination with COPD in the stage of mild exacerbation, which were divided into two groups: the main group and the comparison group. The basic treatment of CP was carried out according to the clinical recommendations of the Russian Gastroenterological Association. Patients of the main group, in addition to basic therapy, received rifaximin (Alfa Normix) for 10 days, and then Subalin-forte for 2 weeks. Patients in the comparison group received only basic therapy. Results. Due to the treatment with the inclusion of rifaximin and Subalin, there is a significant suppression of the phenomenon of “evasion” of the pancreatic-specific enzyme into the blood, an improvement in the exocrine function of the pancreas according to the results of the fecal elastase test and the response of the pancreas to food intake according to the dynamics of uroamylase flow rates and endogenous pancreozymin induction coefficients. Under the influence of the main treatment option, there is an increase in the frequency of normalization of the echogenicity of the pancreas and less often than with traditional therapy, an increase in the pancreas or part of it, blurring and unevenness of the contours persist. In addition, the indicators of ultrasonic histography of the pancreas are significantly improved, and a more pronounced positive dynamics of the clinical manifestations of COPD is observed. Thus, the eradication of SIBO provides a significant increase in the effectiveness of the treatment of patients with a combination of CP and COPD.","PeriodicalId":11555,"journal":{"name":"Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-01-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31146/1682-8658-ecg-204-8-17-27","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

The lack of efficiency in the diagnosis and treatment of chronic pancreatitis (CP) is associated with a number of objective and subjective reasons, one of which is insufficient knowledge about the pathogenesis of the disease, especially when it is combined with other internal diseases, in particular, with chronic obstructive pulmonary disease (COPD). The frequent combination of COPD and CP is associated not only with the frequency of these diseases, but also with the common links of pathogenesis, and a significant place in the pathogenesis of both diseases is occupied by the syndrome of excessive bacterial growth in the small intestine (SIBO). Aim: to increase the effectiveness of the treatment of CP in combination with COPD based on the inclusion of rifaximin and probiotic Subalin in the complex therapy of concomitant diseases. Materials and methods. We examined 128 patients with CP in the stage of exacerbation in combination with COPD in the stage of mild exacerbation, which were divided into two groups: the main group and the comparison group. The basic treatment of CP was carried out according to the clinical recommendations of the Russian Gastroenterological Association. Patients of the main group, in addition to basic therapy, received rifaximin (Alfa Normix) for 10 days, and then Subalin-forte for 2 weeks. Patients in the comparison group received only basic therapy. Results. Due to the treatment with the inclusion of rifaximin and Subalin, there is a significant suppression of the phenomenon of “evasion” of the pancreatic-specific enzyme into the blood, an improvement in the exocrine function of the pancreas according to the results of the fecal elastase test and the response of the pancreas to food intake according to the dynamics of uroamylase flow rates and endogenous pancreozymin induction coefficients. Under the influence of the main treatment option, there is an increase in the frequency of normalization of the echogenicity of the pancreas and less often than with traditional therapy, an increase in the pancreas or part of it, blurring and unevenness of the contours persist. In addition, the indicators of ultrasonic histography of the pancreas are significantly improved, and a more pronounced positive dynamics of the clinical manifestations of COPD is observed. Thus, the eradication of SIBO provides a significant increase in the effectiveness of the treatment of patients with a combination of CP and COPD.
根除小肠细菌过度生长综合征对慢性胰腺炎合并慢性阻塞性肺疾病患者临床表现、胰腺功能状态及结构变化动态及生活质量的影响
慢性胰腺炎(CP)的诊断和治疗效率低下与许多客观和主观原因有关,其中一个原因是对疾病的发病机制了解不足,特别是当它与其他内部疾病,特别是慢性阻塞性肺疾病(COPD)合并时。慢性阻塞性肺病和慢性阻塞性肺病的频繁合并不仅与这两种疾病的发生频率有关,而且在发病机制上也有共同的联系,其中小肠细菌过度生长综合征(SIBO)在两种疾病的发病机制中占有重要地位。目的:在利福昔明与益生菌素素联合治疗伴发疾病的基础上,提高慢性阻塞性肺病合并COPD的治疗效果。材料和方法。我们将128例急性加重期CP合并轻度加重期COPD患者分为两组:主组和对照组。CP的基本治疗是根据俄罗斯胃肠病学协会的临床建议进行的。主组患者在基础治疗的基础上,先给予利福昔明(Alfa Normix)治疗10天,再给予亚伯林-复地治疗2周。对照组患者仅接受基础治疗。结果。由于纳入利福昔明和亚伯灵治疗,胰腺特异性酶“逃避”进入血液的现象得到明显抑制,根据粪便弹性酶试验结果,胰腺的外分泌功能得到改善,根据尿淀淀酶流量和内源性胰酶诱导系数的动态,胰腺对食物摄入的反应得到改善。在主要治疗方案的影响下,胰腺回声恢复正常的频率有所增加,但与传统治疗相比,胰腺或部分胰腺回声增强的频率较低,轮廓持续模糊和不均匀。胰腺超声组织学指标明显改善,慢性阻塞性肺病临床表现阳性动态更加明显。因此,SIBO的根除显著提高了慢性阻塞性肺病合并患者的治疗效果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信